Early-Stage Non-Small Cell Lung Cancer: Addressing the Imperfections - Medscape

1 year ago 42

Please corroborate that you would similar to log retired of Medscape. If you log out, you volition beryllium required to participate your username and password the adjacent clip you visit. Log out Cancel

Thomas E. Stinchcombe, MD, comments connected unmet needs successful the dynamic abstraction of early-stage non–small compartment lung cancer.

While crediting the much caller therapeutic advances, Dr Stinchcombe simultaneously laments the gaps successful the knowing of the finer points of attraction efficacy and toxicities that prevents a much close and informative speech with patients.

Any views expressed supra are the author's ain and bash not needfully bespeak the views of WebMD oregon Medscape.

Cite this: Early-Stage Non-Small Cell Lung Cancer: Addressing the Imperfections - Medscape - Jan 30, 2023.

Authors and Disclosures

Expert

Thomas E. Stinchcombe, MD

Professor, Department of Medicine, Duke Cancer Institute, Thoracic Oncologist, Duke Cancer Institute, Durham, North Carolina

Disclosure: Thomas E. Stinchcombe, MD, has disclosed the pursuing applicable fiscal relationships:
Serve(d) arsenic a director, officer, partner, employee, advisor, consultant, oregon trustee for: EMD Serono; Janssen Oncology; Turning Point Therapeutics; Sanofi/Aventis; GlaxoSmithKline; Genentech/Roche; Daiichi Sankyo
Received probe assistance from: AstraZeneca; Takeda; Regeneron; Seagen